Skip to main content
Premium Trial:

Request an Annual Quote

Prometheus, Bayer Schering in Cancer PGx Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories said today that it has struck a license and development agreement with Bayer Schering Pharma for oncology diagnostics that could net Prometheus as much as $160 million.

Under the non-exclusive agreement, which includes up-front and milestone payments, San Diego-based Prometheus will use its oncology diagnostic platform, which measures expression and activation of specific cancer pathways, to develop oncology tools that could be used to advance and personalize novel cancer therapeutics.

A functional pathway analysis using Prometheus' technology "could allow for a comprehensive analysis of the tumor, patient stratification, and efficacy predictability of individual targeted cancer therapeutics as well as most effective treatment combinations," Bayer Schering Pharma's Head of Global Drug Discovery, Andreas Busch, said in a statement. "Developing such a diagnostic tool constitutes a significant step towards personalized medicine in cancer treatment and we are convinced this will increasingly become the standard of clinical care in oncology."

Prometheus said that the deal could be worth up to $160 million if all drug candidates are successfully developed and obtain regulatory approval.

The Scan

Polarized Science Confidence

A new survey finds that confidence in science among US adults is increasingly polarized, the Associated Press says.

Time to Sit Back and Relax

NPR reports that the US National Institutes of Health has transferred the last of its eligible former research chimpanzees to a sanctuary.

Omicron-Focused Vaccines

The New York Times reports both Pfizer-BioNTech and Moderna have launched trials of SARS-CoV-2 vaccines targeting the Omicron variant.

Nature Papers Present Cloud-Computing Analysis Approach, Transcription Factor With Role in Bacterial Genome Organization

In Nature this week: researchers describe the free, open-source cloud-computing infrastructure Serratus and more.